Anti-arrhythmic action of cycloprotobuxine-A.
Cycloprotobuxine-A (CPB-A) 1-4 mg/kg (1/100-1/25 LD50) produced therapeutic and prophylactic effects which were found to be dose-dependent on experimental arrhythmias induced by BaCl2, aconitine and chloroform. Given at equitoxic doses, the anti-arrhythmic action of CPB-A was as potent as cyclovirobuxine-D (CVB-D) and amiodarone (Amio). However, its therapeutic index (LD50/ED50) was 1.8 times that of CVB-D and 1.2 times that of Amio. The most pronounced effects of CPB-A (0.3-30 mumol/L) on the electrophysiology of ventricular muscle of guinea pig were the lengthening of APD50, APD90 and ERP. This may contribute to its anti-arrhythmic action and suggests that CPB-A most likely belongs to class III anti-arrhythmic drugs (prolongation of APD). Perfused with the same concentration (3 mumol/L), CPB-A brought about more significant increases in APD50, APD90 and ERP than CVB-D and Amio did.
Wang
Y X
YX
Liu
J W
JW
Tan
Y H
YH
Sheng
B H
BH
D000200:Action Potentials / Q000187:drug effects; D000470:Alkaloids / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000889:Anti-Arrhythmia Agents; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D005260:Female; D006168:Guinea Pigs; D008297:Male; D051379:Mice; D051381:Rats; D011919:Rats, Inbred Strains; D014693:Ventricular Fibrillation / Q000517:prevention & control
D000470:Alkaloids; D000889:Anti-Arrhythmia Agents; D004365:Drugs, Chinese Herbal; C062783:cycloprotobuxine A; C032939:cyclovirobuxine D